- Home
- YQ vs FEMY Comparison
YQ vs FEMY Comparison
Compare YQ & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- FEMY
- Stock Information
- Founded
- YQ 2012
- FEMY 2004
- Country
- YQ China
- FEMY United States
- Employees
- YQ N/A
- FEMY N/A
- Industry
- YQ Other Consumer Services
- FEMY Medical/Dental Instruments
- Sector
- YQ Real Estate
- FEMY Health Care
- Exchange
- YQ Nasdaq
- FEMY Nasdaq
- Market Cap
- YQ 36.7M
- FEMY 30.2M
- IPO Year
- YQ 2020
- FEMY 2021
- Fundamental
- Price
- YQ $5.81
- FEMY $0.61
- Analyst Decision
- YQ
- FEMY Strong Buy
- Analyst Count
- YQ 0
- FEMY 3
- Target Price
- YQ N/A
- FEMY $7.33
- AVG Volume (30 Days)
- YQ 47.9K
- FEMY 13.2M
- Earning Date
- YQ 09-03-2025
- FEMY 11-11-2025
- Dividend Yield
- YQ N/A
- FEMY N/A
- EPS Growth
- YQ N/A
- FEMY N/A
- EPS
- YQ N/A
- FEMY N/A
- Revenue
- YQ $20,003,071.00
- FEMY $1,887,016.00
- Revenue This Year
- YQ N/A
- FEMY $103.55
- Revenue Next Year
- YQ N/A
- FEMY $148.13
- P/E Ratio
- YQ N/A
- FEMY N/A
- Revenue Growth
- YQ N/A
- FEMY 98.61
- 52 Week Low
- YQ $1.26
- FEMY $0.31
- 52 Week High
- YQ $6.31
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- YQ 68.92
- FEMY 54.11
- Support Level
- YQ $5.50
- FEMY $0.52
- Resistance Level
- YQ $6.31
- FEMY $0.90
- Average True Range (ATR)
- YQ 0.52
- FEMY 0.13
- MACD
- YQ 0.05
- FEMY 0.01
- Stochastic Oscillator
- YQ 79.54
- FEMY 47.27
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.